New Canadian Medical Marijuana Study Could Be The Hard Data The Cannabis Industry Needs
While marijuana is rapidly gaining popularity, we don’t know a lot about its capabilities. Since it is a Schedule 1 substance in the U.S., researchers find it hard to perform studies. However, it is legal in Canada and researchers there are working on a study that could help us understand how effective cannabis is in treating various illnesses. While there are many anecdotal pieces of evidence of cannabis helping treat various health conditions, there is only one FDA-approved drug in the market. The Medical Cannabis Real-World Evidence Study will have at least 2,000 participants who have been using cannabis for a variety of issues.
The study will utilize a portal run by Canadian pharmacy retailer Shoppers Drug Mart that contains accurate and reliable information about the medical cannabis products it sells including dried flower, oils, extracts, edibles, and topical preparations.
Users can now be confident about the accuracy of the product. Knowing a specific strain in a product will help one understand the impact it offers for a certain illness. One major restriction of the study is that there is no control group and it is highly dependent on the information that patients report regarding the effectiveness of a particular product. Regardless, this study is quite important since it will establish that cannabis does offer some help in treating health conditions. This could even help the FDA change regulations regarding cannabis sale and use. The study has not yet started and is still accepting participants. It is slated to be completed by next year.
Read Full Article: https://www.fool.com
CBD is one of many powerful cannabinoids found in hemp known for helping to support our body and mind. Here at Healing Dragon CBD we do not intend to make unfounded medical claims about the health benefits of CBD. The FDA has not confirmed that CBD cures, treats, or prevents any diseases or conditions. Before reading this article please take a moment to read our full disclosure statement.